145 related articles for article (PubMed ID: 8889080)
21. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
[TBL] [Abstract][Full Text] [Related]
22. Lack of awareness and nonadherence in schizophrenia.
Kozuki Y; Froelicher ES
West J Nurs Res; 2003 Feb; 25(1):57-74. PubMed ID: 12584964
[TBL] [Abstract][Full Text] [Related]
23. Medicine taking decisions: schizophrenia in comparison to asthma and epilepsy.
Marland GR; Cash K
J Psychiatr Ment Health Nurs; 2005 Apr; 12(2):163-72. PubMed ID: 15788033
[TBL] [Abstract][Full Text] [Related]
24. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of antipsychotic medication taking in people with schizophrenia.
McCann TV; Deans C; Clark E; Lu S
Int J Ment Health Nurs; 2008 Dec; 17(6):428-38. PubMed ID: 19128290
[TBL] [Abstract][Full Text] [Related]
26. An economic review of compliance with medication therapy in the treatment of schizophrenia.
Thieda P; Beard S; Richter A; Kane J
Psychiatr Serv; 2003 Apr; 54(4):508-16. PubMed ID: 12663838
[TBL] [Abstract][Full Text] [Related]
27. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia.
Tsang HW; Fung KM; Corrigan PW
J Behav Ther Exp Psychiatry; 2009 Mar; 40(1):3-14. PubMed ID: 18417098
[TBL] [Abstract][Full Text] [Related]
28. [Patient education about neuroleptic treatment, can it reduce costs? A pilot study].
Favrod J; Huguelet P; Chambon O
Encephale; 1996; 22(5):331-6. PubMed ID: 9035989
[TBL] [Abstract][Full Text] [Related]
29. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Perkins DO; Johnson JL; Hamer RM; Zipursky RB; Keefe RS; Centorrhino F; Green AI; Glick IB; Kahn RS; Sharma T; Tohen M; McEvoy JP; Weiden PJ; Lieberman JA;
Schizophr Res; 2006 Mar; 83(1):53-63. PubMed ID: 16529910
[TBL] [Abstract][Full Text] [Related]
30. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
Patel MX; de Zoysa N; Bernadt M; David AS
J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
[TBL] [Abstract][Full Text] [Related]
31. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
Hornung WP; Schonauer K; Feldmann R; Mönking HS
Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
[TBL] [Abstract][Full Text] [Related]
32. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia.
Patterson TL; Lacro J; McKibbin CL; Moscona S; Hughs T; Jeste DV
J Clin Psychopharmacol; 2002 Feb; 22(1):11-9. PubMed ID: 11799337
[TBL] [Abstract][Full Text] [Related]
33. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data.
Rijcken CA; Tobi H; Vergouwen AC; de Jong-van den Berg LT
Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):365-70. PubMed ID: 15170765
[TBL] [Abstract][Full Text] [Related]
34. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
35. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
36. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
[TBL] [Abstract][Full Text] [Related]
37. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
[TBL] [Abstract][Full Text] [Related]
38. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.
Hogan TP; Awad AG; Eastwood R
Psychol Med; 1983 Feb; 13(1):177-83. PubMed ID: 6133297
[TBL] [Abstract][Full Text] [Related]
39. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
40. The impact of subjective well-being under neuroleptic treatment on compliance and remission.
de Millas W; Lambert M; Naber D
Dialogues Clin Neurosci; 2006; 8(1):131-6. PubMed ID: 16640124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
